Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection

Background Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. Rifaximin is an antibiotic that offers marginal resistance to C. difficile bacteria. This study was conducted to evaluate the efficacy of rifaximin in metronidazole non-responsive CDI patients. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqas, Muhammad, Mohib, Khadija, Saleem, Aniqa, LNU, Mahak, Arjumand, Sabeen, Khalil, Hafiz Habib Ur Rehman, Nosheen, Rukhshanda, Abbas, Sharmeen, Maqsood, Kanza M, Abbas, Kiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107305/
https://www.ncbi.nlm.nih.gov/pubmed/35582554
http://dx.doi.org/10.7759/cureus.24140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107305/
https://www.ncbi.nlm.nih.gov/pubmed/35582554
http://dx.doi.org/10.7759/cureus.24140

Ejemplares similares